COVID-19 impact on Immunohistochemistry (IHC) Market worth USD 2.7 billion by 2025 | Leading Companies are F. Hoffmann-La Roche Ltd (Switzerland), Agilent Technologies, Inc. (US) Danaher Corporation (US), PHC Holding Corporation (Japan), Biocare Medical,

According to the new market research report "Immunohistochemistry/IHC Market by Product (Antibodies, Reagents (Chromogenic Substrates), Kits), Application (Diagnostics (Cancer, Infectious), Research, Forensic), End User (Hospitals, Diagnostic Laboratories, Academic) - Global Forecast to 2025", published by MarketsandMarkets™, analyzes and studies the major market drivers, restraints/challenges, and opportunities in North America, Europe, Asia-Pacific, and the Rest of the world (RoW).

The Immunohistochemistry Market is projected to reach USD 2.7 billion by 2025 from USD 1.9 billion in 2020, at a CAGR of 6.6% during the forecast period.

Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=121632939#utm_source=Openpr&utm_medium=paidpr

COVID-19 impact on the global IHC market
Globally, the COVID-19 outbreak has impacted every aspect of the diagnostic industry, including IHC testing. In the last few months, the number of patient visits to hospitals has reduced significantly, despite emergency OPD and laboratory services being available in hospitals.

After commencing cancer surgeries or any other surgeries, surgeons run an IHC test/assay to decide the best treatment for patients. However, due to lockdowns in Q1 & Q2 2020 in many countries, the number of elective surgeries and diagnostic tests has significantly reduced. As a result, the number of IHC tests has reduced. This has significantly reduced the sales of IHC products in Q1 2020 and, to some extent, in Q2 2020.

The increasing incidence and prevalence of cancer, technological advancements in IHC, and the availability of reimbursement for IHC tests are the major factors driving the growth of this market.

The cancer segment accounted for the largest share of the diagnostic segment in the IHC Market

Based on diseases, the diagnostic applications is further segmented into infectious diseases, cancer, autoimmune diseases, neurology, nephrological diseases, and other diseases (cardiovascular diseases, ophthalmology, and diabetes). In 2019, the cancer diagnostics segment accounted for the largest share of the Immunohistochemistry Market for diagnostic applications Growing use of IHC tests for cancer diagostics and increasing prevalence & incidence of cancer to fuel market growth.

Browse in-depth TOC on "Immunohistochemistry/IHC Market"
247 – Tables
28 – Figures
236 – Pages
Get 10% Customization on this Research Report:
https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=121632939#utm_source=Openpr&utm_medium=paidpr

Hospitals & diagnostic laboratories accounted for the fastest-growing end user segment of the IHC Market

Based on end user, the Immunohistochemistry Market is segmented into hospitals & diagnostic laboratories, academic & research institutes, and other end users (contract research organizations, pharma & biopharma companies, and forensic laboratories). The hospitals & diagnostic laboratories segment is estimated to grow at the highest CAGR during the forecast period. The growth of this segment is majorly attributed to factors such as the rising burden of cancer and the favorable reimbursement scenario for IHC tests.

North America accounted for the largest share of the IHC Market

North America accounted for the largest share of the Immunohistochemistry Market, followed by Europe in 2019. The growth in this regional market can be attributed to the presence of major players operating in the market in the US, rising incidence of cancer and infectious diseases, and the increasing adoption of companion diagnostic assay kits.

Request for Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=121632939#utm_source=Openpr&utm_medium=paidpr

Key Players

The prominent players operating in the IHC Market are F. Hoffmann-La Roche Ltd (Switzerland), Agilent Technologies, Inc. (US), Danaher Corporation (US), PHC Holding Corporation (Japan), Biocare Medical, LLC. (US), and Merck KGaA (Germany).

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets' flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

This release was published on openPR.